Hemodynamic Adaptation and Cardiac Effects of High-Flow Arteriovenous Access in Hemodialysis Patients: A Prospective Study
Journal of Clinical Medicine · 26.06.2025 · 14 (13) · 4556
DOI: 10.3390/jcm14134556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.06.2025. Verfasst von Yaeni Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Transplantation Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Kor…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A vascular access blood flow (Qa) to cardiac output (CO) ratio greater than 0.3 increases the risk of high-output heart failure (HOHF). This study analyzed the characteristics and risk factors associated with a high Qa/CO ratio and effective CO (COef) in these patients over one year.
Methods
This prospective study enrolled 142 hemodialysis (HD) patients, divided by the Qa/CO ratio. Baseline and one-year hemodynamics were measured: volume by bioimpedance, CO by echocardiography, Qa and brachial flow by transonic and ultrasound. Risk factors for HOHF were analyzed using receiver operating characteristic (ROC) curves and multivariable regression.
Results
The study population was 66% male, mean age of 65, with 71% using arteriovenous fistulae (AVF) for vascular access. In the high Qa/CO group, cases of younger ages (62 vs. 67 years, p = 0.040) with upper arm access (73.1% vs. 32.8%, p < 0.001) were more prevalent, and diastolic blood pressure (DBP) was higher (76.8 ± 15.1 vs. 66.7 ± 14.4 mmHg, p = 0.002). Independent risk factors for high Qa/CO were elevated DBP (odds ratio [OR]: 1.080; 95% confidence interval [CI]: 1.028–1.134), upper arm access (OR: 8.113; 95% CI: 1.842–35.741), low resistive index (RI) (OR: 0.000; 95% CI: 0.000–0.417), and COef (OR: 0.164; 95% CI: 0.065–0.416). After one year, the high Qa/CO group showed significant increases in CO and COef (4.82 ± 1.25 L/min vs. 6.16 ± 2.05 L/min, p = 0.007, and 2.84 ± 0.95 L/min to 4.40 ± 1.89 L/min, p = 0.001, respectively). A baseline Qa cutoff value of 1.4 L/min demonstrated high diagnostic efficacy in identifying the high Qa/CO group.
Conclusions
High Qa/CO ratios increase overt HOHF risk due to cardiac strain. This study reveals AV access-driven cardiac adaptations in patients with high Qa/CO and low COef, emphasizing the necessity for ongoing clinical and hemodynamic monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Transplantation Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, Dialysis Access Center, Sahmyook Medical Center, 82 Mangu-ro, Dongdaemun-gu, Seoul 02500, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, Dialysis Access Center, Sahmyook Medical Center, 82 Mangu-ro, Dongdaemun-gu, Seoul 02500, Republic of Korea.
ORCID-Profile: Yaeni Kim, Sunryoung Choi
Zitieren
APA
Kim, Y., Kim, J. H., Woo, J., Choi, O., Lee, M., & Choi, S. (2025). Hemodynamic Adaptation and Cardiac Effects of High-Flow Arteriovenous Access in Hemodialysis Patients: A Prospective Study. Journal of Clinical Medicine, 14(13), 4556. https://doi.org/10.3390/jcm14134556
Vancouver
Kim Y, Kim JH, Woo J, Choi O, Lee M, Choi S. Hemodynamic Adaptation and Cardiac Effects of High-Flow Arteriovenous Access in Hemodialysis Patients: A Prospective Study. Journal of Clinical Medicine. 2025;14(13):4556. doi:10.3390/jcm14134556
BibTeX
@article{Kim2025,
author = {Kim, Yaeni and Kim, Ji-Hye and Woo, Juyeon and Choi, Oknan and Lee, Mina and Choi, Sunryoung},
title = {Hemodynamic Adaptation and Cardiac Effects of High-Flow Arteriovenous Access in Hemodialysis Patients: A Prospective Study},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {13},
pages = {4556},
doi = {10.3390/jcm14134556}
}
EUVIMED